Company Overview and News
Dicerna Pharmaceuticals (DRNA) may be headed down the same hole that buried Genta, an infamous biotech darling-turned-disaster. (60-0)
Good afternoon ladies and gentlemen, and welcome to the miRagen Therapeutics Third Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, instructions will follow at that time. As a reminder, today’s call is being recorded. (43-0)
LONDON, UK / ACCESSWIRE / October 16, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for Miragen Therapeutics, Inc. (NASDAQ: MGEN) ("Miragen"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=MGEN. The Company announced on October 13, 2017, new interim results from its ongoing Phase-1 clinical trial, designed to evaluate the safety, efficacy, and pharmacokinetics of MRG-106 in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL). (58-0)
* Miragen Therapeutics presents new clinical data suggesting positive impact from systemically administered MRG-106 on mycosis fungoides form of cutaneous T-cell lymphoma at EORTC global task force meeting (43-0)
August 16, 2017 - Boulder Ventures V, L.p. has filed a SC 13D/A form disclosing ownership of 82,490 shares of Miragen Therapeutics (NASDAQ:MGEN) corresponding to a(n) 0.4 ownership percentage.
Good afternoon ladies and gentlemen, and welcome to the miRagen Therapeutics Second Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, instructions will be given at that time. As a reminder, this conference is being recorded.
2017-10-28 - Wilton
2017-10-25 - Wilton
2017-10-10 - Wilton
2017-10-09 - Wilton
2017-08-25 - Wilton